Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
McKesson
Dow
Johnson and Johnson
Baxter

Last Updated: August 15, 2022

DEFINITY RT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Definity Rt patents expire, and what generic alternatives are available?

Definity Rt is a drug marketed by Lantheus Medcl and is included in one NDA. There are six patents protecting this drug.

This drug has forty-seven patent family members in fifteen countries.

The generic ingredient in DEFINITY RT is perflutren. One supplier is listed for this compound. Additional details are available on the perflutren profile page.

DrugPatentWatch® Generic Entry Outlook for Definity Rt

Definity Rt was eligible for patent challenges on July 31, 2005.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for DEFINITY RT
International Patents:47
US Patents:6
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 59
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in DEFINITY RT?DEFINITY RT excipients list
DailyMed Link:DEFINITY RT at DailyMed
Drug patent expirations by year for DEFINITY RT
Recent Clinical Trials for DEFINITY RT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of MichiganPhase 2
National Cancer Institute (NCI)Phase 2
Institute of Liver and Biliary Sciences, IndiaN/A

See all DEFINITY RT clinical trials

Pharmacology for DEFINITY RT

US Patents and Regulatory Information for DEFINITY RT

DEFINITY RT is protected by six US patents.

Patents protecting DEFINITY RT

Lipid-encapsulated gas microsphere compositions and related methods
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Lipid-encapsulated gas microsphere compositions and related methods
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Methods for making ultrasound contrast agents
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Methods and devices for preparation of ultrasound contrast agents
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Methods for making ultrasound contrast agents
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Methods for making ultrasound contrast agents
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for DEFINITY RT

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Lantheus EU Limited Luminity perflutren EMEA/H/C/000654
This medicinal product is for diagnostic use only.Luminity is an ultrasound contrast-enhancing agent for use in patients in whom non-contrast echocardiography was suboptimal (suboptimal is considered to indicate that at least two of six segments in the 4- or 2-chamber view of the ventricular border were not evaluable) and who have suspected or established coronary artery disease, to provide opacification of cardiac chambers and improvement of left ventricular endocardial border delineation at both rest and stress.
Authorised no no no 2006-09-20
GE Healthcare AS Optison perflutren EMEA/H/C/000166
This medicinal product is for diagnostic use only.Optison is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left-ventricular-endocardial-border delineation with resulting improvement in wall-motion visualisation.Optison should only be used in patients where the study without contrast enhancement is inconclusive.
Authorised no no no 1998-05-17
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for DEFINITY RT

See the table below for patents covering DEFINITY RT around the world.

Country Patent Number Title Estimated Expiration
Greece 3036289 See Plans and Pricing
Brazil 9604786 See Plans and Pricing
Australia 6270396 See Plans and Pricing
Japan 4215820 See Plans and Pricing
Mexico 9709717 APARATO Y METODO PARA HACER VESICULAS RELLENAS DE GAS DE TAMAƑO OPTIMO. (APPARATUS AND METHOD FOR MAKING GAS-FILLED VESICLES OF OPTIMAL SIZE.) See Plans and Pricing
European Patent Office 0616508 LIPOSOMES REMPLIS DE GAZ ET LEUR UTILISATION EN TANT QU'AGENTS DE CONTRASTE ULTRASONORE (GAS FILLED LIPOSOMES AND THEIR USE AS ULTRASONIC CONTRAST AGENTS) See Plans and Pricing
Austria 235228 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for DEFINITY RT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0712293 SPC/GB07/031 United Kingdom See Plans and Pricing PRODUCT NAME: PERFLUTREN-CONTAINING LIPID MICROSPHERES; REGISTERED: UK EU/1/06/361/001 20060920
0712293 CA 2007 00027 Denmark See Plans and Pricing
0712293 300267 Netherlands See Plans and Pricing 300267, 20140520, EXPIRES: 20190519
0712293 C300267 Netherlands See Plans and Pricing PRODUCT NAME: PERFLUTREN BEVATTENDE LIPIDE-MICROBOLLEN; REGISTRATION NO/DATE: EU/1/06/361/001 20060920
0712293 0790017-8 Sweden See Plans and Pricing PRODUCT NAME: LIPIDMIKROSFAERER INNEHALLANDE PERFLUTREN; REG. NO/DATE: EU/1/06/361/001 20060920
0712293 91325 Luxembourg See Plans and Pricing PRODUCT NMAE. LUMINITY; REGISTRATION DATE: 20060920
0712293 SPC018/2007 Ireland See Plans and Pricing SPC018/2007: 20071012, EXPIRES: 20190519
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
AstraZeneca
Merck
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.